S. Chatzikyriakou

Effect of statins on collagen type I degradation in patients with coronary artery disease and atrial fibrillation.

E. Maltezos, D. Stakos, D. Tziakas, 2008, The American journal of cardiology.

Cholesterol composition of erythrocyte membranes and its association with clinical presentation of coronary artery disease

J. Kaski, I. Tentes, D. Stakos, 2008, Coronary artery disease.

Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation.

E. Maltezos, D. Stakos, D. Tziakas, 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension

E. Maltezos, D. Stakos, D. Tziakas, 2007, Expert opinion on pharmacotherapy.

Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure

D. Stakos, D. Tziakas, G. Chalikias, 2012, Quality of Life Research.

Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy.

D. Stakos, D. Tziakas, G. Chalikias, 2010, European journal of pharmacology.

Interleukin-8 is increased in the membrane of circulating erythrocytes in patients with acute coronary syndrome.

J. Kaski, I. Tentes, D. Stakos, 2008, European heart journal.

Resolution of symptoms and serum peptides of collagen type I turnover in acute heart failure patients

E. Maltezos, D. Stakos, D. Tziakas, 2009, Acta cardiologica.

Serum levels of collagen type‐I degradation markers are associated with vascular stiffness in chronic heart failure patients

E. Maltezos, D. Stakos, D. Tziakas, 2008, European journal of heart failure.